Ionis Pharmaceuticals Competitors and Similar CompaniesClear all

Ionis Pharmaceuticals's competitors and similar companies include Bluebird Bio, Arrowhead Pharmaceuticals, Reata Pharmaceuticals, Alnylam Pharmaceuticals, Ultragenyx Pharmaceutical, Lannett, Intellia Therapeutics and Sarepta Therapeutics.
Ionis Pharmaceuticals
Ionis Pharmaceuticals
Ionis Pharmaceuticals (formerly known as Isis Pharmaceuticals) is a company that discovers and develops RNA-targeted therapeutics.
Bluebird Bio
Bluebird Bio
Bluebird Bio is a developer of gene therapies for severe genetic diseases and cancer.
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them.
Reata Pharmaceuticals
Reata Pharmaceuticals
Reata Pharmaceuticals is a biopharmaceutical company that develops therapeutics for patients with serious or life-threatening diseases.
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals
Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi.
Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical focuses on the development of various products for the treatment of rare and ultra-rare diseases.
Lannett
Lannett
Lannett is a company that specializes in pharmaceutical product families.
Intellia Therapeutics
Intellia Therapeutics
Intellia is developing therapeutic products to help people with genetic diseases.
Sarepta Therapeutics
Sarepta Therapeutics
Sarepta Therapeutics is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapeutics, gene therapy and, other genetic therapeutic modalities for the treatment of rare diseases.
Founding Date
Founding Date
1989
Founding Date
1992
Founding Date
2004
Founding Date
2002
Founding Date
2002
Founding Date
2010
Founding Date
1942
Founding Date
2014
Founding Date
1980
Type
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Carlsbad, US HQ
Locations
Cambridge, US HQ
Paris, FR
München, DE
Athens, GR
Milano, IT
Utrecht, NL
Zug, CH
see more
Locations
Pasadena, US HQ
Madison, US
San Diego, US
Locations
Plano, US HQ
Irving, US
Plano, US
Locations
Cambridge, US HQ
Paris, FR
Milan, IT
Tokyo, JP
Amsterdam, NL
Stockholm, SE
Zug, CH
see more
Locations
Novato, US HQ
Locations
Trevose, US HQ
Philadelphia, US
Locations
Cambridge, US HQ
Locations
Cambridge, US HQ
Dublin, IE
Zug, CH
Providence, US
Employees
Employees
7577% decrease
Employees
1,2134% increase
Employees
13416% increase
Employees
22079% increase
Employees
1,32324% increase
Employees
74021% increase
Employees
81015% decrease
Employees
27028% increase
Employees
8403% decrease
Valuation ($)
Valuation ($)
6.8 b
Valuation ($)
324.1 m
Valuation ($)
3.3 b
Valuation ($)
6.5 b
Valuation ($)
21.9 b
Valuation ($)
2.7 b
Valuation ($)
7.4 m
Valuation ($)
2.8 b
Valuation ($)
11.1 b
Twitter followers
Twitter followers
4.4 k
Twitter followers
10.6 k
Twitter followers
3.3 k
Twitter followers
1.5 k
Twitter followers
16.3 k
Twitter followers
N/A
Twitter followers
N/A
Twitter followers
9.3 k
Twitter followers
5 k
Number of tweets (last 30 days)
Number of tweets (last 30 days)
5
Number of tweets (last 30 days)
8
Number of tweets (last 30 days)
4
Number of tweets (last 30 days)
10
Number of tweets (last 30 days)
23
Number of tweets (last 30 days)
N/A
Number of tweets (last 30 days)
N/A
Number of tweets (last 30 days)
7
Number of tweets (last 30 days)
13
Average likes per tweet (last 30 days)
Average likes per tweet (last 30 days)
4
Average likes per tweet (last 30 days)
5.1
Average likes per tweet (last 30 days)
36
Average likes per tweet (last 30 days)
3.4
Average likes per tweet (last 30 days)
3
Average likes per tweet (last 30 days)
N/A
Average likes per tweet (last 30 days)
N/A
Average likes per tweet (last 30 days)
23.3
Average likes per tweet (last 30 days)
40.6
Percentage of tweets with engagement (last 30 days)
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
75%
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
60%
Percentage of tweets with engagement (last 30 days)
86.96%
Percentage of tweets with engagement (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
69.23%
Employee Rating
Employee Rating
3.6
Employee Rating
3.6
Employee Rating
3.9
Employee Rating
3.6
Employee Rating
4.2
Employee Rating
4.3
Employee Rating
2.1
Employee Rating
4
Employee Rating
4.1

Financial

Revenue (est.)
Revenue (est.)
$587.4m (FY, 2022)
Revenue (est.)
$3.6m (FY, 2022)
Revenue (est.)
$243.2m (FY, 2022)
Revenue (est.)
$2.2m (FY, 2022)
Revenue (est.)
$1b (FY, 2022)
Revenue (est.)
$363.3m (FY, 2022)
Revenue (est.)
$340.6m (FY, 2022)
Revenue (est.)
$52.1m (FY, 2022)
Revenue (est.)
$933m (FY, 2022)
Cost of goods
Cost of goods
$14.1m (FY, 2022)
Cost of goods
N/A
Cost of goods
N/A
Cost of goods
N/A
Cost of goods
$140.2m (FY, 2022)
Cost of goods
N/A
Cost of goods
N/A
Cost of goods
N/A
Cost of goods
N/A
Gross profit
Gross profit
$573.3m (FY, 2022)
Gross profit
N/A
Gross profit
N/A
Gross profit
N/A
Gross profit
$897.2m (FY, 2022)
Gross profit
N/A
Gross profit
$33.2m (FY, 2022)
Gross profit
N/A
Gross profit
N/A
Net income
Net income
($269.7m) (FY, 2022)
Net income
($266.6m) (FY, 2022)
Net income
($176.5m) (FY, 2022)
Net income
($311.9m) (FY, 2022)
Net income
($1.1b) (FY, 2022)
Net income
($707.4m) (FY, 2022)
Net income
($231.6m) (FY, 2022)
Net income
($474.2m) (FY, 2022)
Net income
($703.5m) (FY, 2022)

Operating

Patents Issued
Patents Issued
N/A
Patents Issued
N/A
Patents Issued
359 (FY, 2016)
Patents Issued
240 (FY, 2016)
Patents Issued
N/A
Patents Issued
N/A
Patents Issued
N/A
Patents Issued
N/A
Patents Issued
N/A
Phase I Trials Products
Phase I Trials Products
6 (FY, 2020)
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
2 (FY, 2016)
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase II Trials Products
Phase II Trials Products
24 (FY, 2020)
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
4 (FY, 2016)
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase III Trials Products
Phase III Trials Products
6 (FY, 2020)
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
1 (FY, 2016)
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
N/A

Funding

Total funding raised
Total funding raised
N/A
Total funding raised
$ 409m
Total funding raised
$ 147.1m
Total funding raised
$ 468.9m
Total funding raised
$ 1.5b
Total funding raised
$ 200.1m
Total funding raised
N/A
Total funding raised
N/A
Total funding raised
N/A
For sources of this data, please see the company profile

View Company Profiles

Bluebird Bio
HQ
Cambridge, US
Employees
1,213↑ 4% increase

Bluebird Bio is a developer of gene therapies for severe genetic diseases and cancer.

View company
Arrowhead Pharmaceuticals
HQ
Pasadena, US
Employees
134↑ 16% increase

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them.

View company
Reata Pharmaceuticals
HQ
Plano, US
Employees
220

Reata Pharmaceuticals is a biopharmaceutical company that develops therapeutics for patients with serious or life-threatening diseases.

View company
Alnylam Pharmaceuticals
HQ
Cambridge, US
Employees
1,323↑ 24% increase

Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi.

View company